Anebulo Pharmaceuticals (ANEB) Stock Price, News & Analysis

Company Overview

Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB) is a clinical‐stage biopharmaceutical company focused on the development of intranasal therapies for the acute treatment of migraine. Its lead product candidate, ANEB-001, is an intranasal formulation of dihydroergotamine mesylate designed to provide rapid relief from migraine attacks while reducing common gastrointestinal side effects associated with oral treatments.

The company is advancing ANEB-001 through pivotal trials in the United States and plans to submit a new drug application to the U.S. Food and Drug Administration upon completion of these studies. Anebulo has established manufacturing and distribution strategies to support future commercialization, aiming to deliver a differentiated option for patients who require fast-acting, non-oral migraine relief.

Founded in 2019 and headquartered in Campbell, California, Anebulo Pharmaceuticals brings together a team of industry veterans in drug delivery and neurology. By leveraging proprietary intranasal delivery technology, the company seeks to address unmet needs in migraine care and expand its development pipeline in related therapeutic areas.

Key Stats

• Today's Range: $0.46 to $0.55
• 50-Day Range: $0.33 to $1.07
• 52-Week Range: $0.30 to $3.42
• Volume: 1,358 shs
• Average Volume: 56,483 shs
• Market Capitalization: $18.86 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $3.00
• Consensus Rating: Reduce

Anebulo Pharmaceuticals Stock Analysis - MarketRank™

Anebulo Pharmaceuticals scored higher than 17% of companies evaluated by MarketBeat, and ranked 789th out of 857 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.8 / 5
• Analyst Rating: Reduce

Consensus Rating

Anebulo Pharmaceuticals has received a consensus rating of Reduce. The company's average rating score is 1.50, and is based on no strong buy ratings, no buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

Anebulo Pharmaceuticals has a consensus price target of $3.00, representing about 548.6% upside from its current price of $0.46.

Amount of Analyst Coverage

Anebulo Pharmaceuticals has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Anebulo Pharmaceuticals is -2.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Anebulo Pharmaceuticals is -2.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Anebulo Pharmaceuticals has a P/B Ratio of 1.65. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for ANEB.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Anebulo Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Anebulo Pharmaceuticals does not have a long track record of dividend growth.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for Anebulo Pharmaceuticals this week, compared to 1 article on an average week.

Company Ownership

• Score: 1.1 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Anebulo Pharmaceuticals insiders have not sold or bought any company stock.

Percentage Held by Insiders

80.60% of the stock of Anebulo Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

28.40% of the stock of Anebulo Pharmaceuticals is held by institutions.

ANEB Stock Analysis - Frequently Asked Questions

How have ANEB shares performed this year?

Anebulo Pharmaceuticals' stock was trading at $1.01 at the beginning of 2026. Since then, ANEB shares have decreased by 54.2% and is now trading at $0.4625.

How were Anebulo Pharmaceuticals' earnings last quarter?

Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB) announced its quarterly earnings data on Friday, February, 13th. The company reported ($0.05) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.13) by $0.08.

When did Anebulo Pharmaceuticals IPO?

Anebulo Pharmaceuticals (ANEB) raised $21 million in an initial public offering on Friday, May 7th 2021. The company issued 3,000,000 shares at a price of $6.00-$8.00 per share. The Benchmark Company served as the underwriter for the IPO.

How do I buy shares of Anebulo Pharmaceuticals?

Shares of ANEB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Anebulo Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Anebulo Pharmaceuticals investors own include Hecla Mining (HL), Li Auto (LI), Norwegian Cruise Line (NCLH), PAR Technology (PAR), Transdigm Group (TDG) and Trade Desk (TTD).

Company Calendar

• Last Earnings: 2/13/2026
• Today: 5/06/2026
• Next Earnings (Estimated): 5/07/2026
• Fiscal Year End: 6/30/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ANEB
• CIK: 1815974
• Web: www.anebulo.com
• Phone: 512-598-0931
• Fax: N/A
• Employees: 4
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Anebulo Pharmaceuticals: $3.00
• High Price Target: $3.00
• Low Price Target: $3.00
• Potential Upside/Downside: +548.6%
• Consensus Rating: Reduce
• Rating Score (0-4): 1.50
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.19)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$8.48 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -74.57%
• Return on Assets: -68.96%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 6.24
• Quick Ratio: 6.24

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.28 per share
• Price / Book: 1.65

Miscellaneous

• Outstanding Shares: 40,785,000
• Free Float: 7,912,000
• Market Cap: $18.86 million
• Optionable: Not Optionable
• Beta: -1.93